12-Lipoxygenase Inhibition Improves Glycemia and Obesity-associated Inflammation in Male Human Gene Replacement Mice
Endocrinology · 2025
DOI: 10.1210/endocr/bqaf069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2025. Verfasst von Kerim B Kaylan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Arachidonate 12-Lipoxygenase, Obesity, Inflammation, Lipoxygenase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Obesity-associated inflammation is characterized by macrophage infiltration into peripheral tissues, contributing to the progression of prediabetes and type 2 diabetes. 12-lipoxygenase (12-LOX) catalyzes the formation of pro-inflammatory eicosanoids and promotes the migration of macrophages, yet its role in obesity-associated inflammation remains incompletely understood. Furthermore, differences between mouse and human orthologs of 12-LOX have limited efforts to study existing pharmacologic inhibitors of 12-LOX. In this study, we used a human gene replacement mouse model in which the gene encoding mouse 12-LOX (Alox15) is replaced by the human ALOX12 gene. As a model of obesity and dysglycemia, we administered male mice a high-fat diet. We subsequently investigated the effects of VLX-1005, a potent and selective small molecule inhibitor of human 12-LOX. Oral administration of VLX-1005 resulted in improved glucose homeostasis, decreased β-cell dedifferentiation, and reduced macrophage infiltration in islets and adipose tissue. Analysis of the stromal vascular fraction from adipose tissue showed a reduction in myeloid cells and cytokine expression with VLX-1005 treatment, indicating decreased adipose tissue inflammation. In a distinct mouse model in which Alox15 was selectively deleted in myeloid cells, we observed decreased β-cell dedifferentiation and reduced macrophage infiltration in both islets and adipose tissue, suggesting that the effects of VLX-1005 may relate to the inhibition of 12-LOX in macrophages. These findings highlight 12-LOX as a key factor in obesity-associated inflammation and suggest that 12-LOX inhibition could serve as a therapeutic strategy to improve glucose homeostasis and peripheral inflammation in the setting of obesity and type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
- Department of Pharmacology, New York Medical College, Valhalla, NY 10595, USA.
- Veralox Therapeutics, Frederick, MD 21704, USA.
ORCID-Profile: Kerim B Kaylan, Titli Nargis, Raghavendra G Mirmira, Sarah A Tersey
Förderung
- NIDDK NIH HHS
- NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Kaylan, K. B., Nargis, T., Figatner, K., Wang, J. E., Pratuangtham, S., Chakraborty, A., Casimiro, I., Nadler, J. L., Boxer, M. B., Maloney, D. J., Anderson, R. M., Mirmira, R. G., & Tersey, S. A. (2025). 12-Lipoxygenase Inhibition Improves Glycemia and Obesity-associated Inflammation in Male Human Gene Replacement Mice. Endocrinology. https://doi.org/10.1210/endocr/bqaf069
Vancouver
Kaylan KB, Nargis T, Figatner K, Wang JE, Pratuangtham S, Chakraborty A, et al. 12-Lipoxygenase Inhibition Improves Glycemia and Obesity-associated Inflammation in Male Human Gene Replacement Mice. Endocrinology. 2025. doi:10.1210/endocr/bqaf069
BibTeX
@article{Kaylan2025,
author = {Kaylan, Kerim B and Nargis, Titli and Figatner, Kayla and Wang, Jiayi E and Pratuangtham, Sarida and Chakraborty, Advaita and Casimiro, Isabel and Nadler, Jerry L and Boxer, Matthew B and Maloney, David J and Anderson, Ryan M and Mirmira, Raghavendra G and Tersey, Sarah A},
title = {12-Lipoxygenase Inhibition Improves Glycemia and Obesity-associated Inflammation in Male Human Gene Replacement Mice},
journal = {Endocrinology},
year = {2025},
doi = {10.1210/endocr/bqaf069}
}
EUVIMED